Finally, promising disease control and survival benefits, with a manageable safety profile, have been observed with alpelisib plus fulvestrant in a Phase Ib study (NCT01219699) in patients with PIK3CA-altered estrogen receptor-positive, HER2–advanced breast cancer (ABC) [22, 23]. The gene discussed is PIK3CA; the disease is breast carcinoma.